美银全球研究（Bofa Global Research）对Moderna, Inc.的评级态度发生重大转变——将其从“跑输大盘”（Underperform）上调至“中性”（Neutral）。同时，该机构设定的目标股价也迎来戏剧性跃升，由原先的40美元一举提至170美元，增幅惊人。
这一调整，不仅是对Moderna, Inc.前期市场表现的一次重新评估，更折射出机构对其未来增长潜力的信心变化。在生物科技行业波动加剧、市场情绪多变的背景下，美银全球研究此举无疑为投资者提供了新的参考坐标。
Moderna, Inc.股价能否在新目标价的指引下持续走强？市场将密切关注其后续表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.